李靖欣，博士，教授，主任医师，博士生导师。曾主持国家自然科学基金优秀青年科学基金和江苏省自然科学基金杰出青年基金。中国疫苗行业协会疫苗临床研究分会副主任委员，中华预防医学会疫苗临床专业委员会常委，主要从事疫苗临床评价和免疫策略研究。省“333工程”第三层次培养对象。2016年以第三完成人获江苏省科学技术奖一等奖，2022年以第一完成人获江苏省科学技术奖二等奖。研究成果以通讯或第一作者在Nature Medicine、Lancet Respiratory Medicine、Lancet Infectious Diseases、Lancet Global Health等高水平学术期刊上发表共58篇。
研究方向：
疫苗临床流行病学
联系方式：
地址：江苏省南京市江宁区龙眠大道101号:
邮箱：jingxin910@njmu.edu.cn
科研项目：
1. 国家重点研发计划课题（2023YFC2307601），疫苗免疫保护效应及安全性特征研究，2023.12-2026.11，260万，在研，主持；
2. 国家自然科学基金委员会, 青年科学基金项目（B类）[原优秀青年科学基金项目], 82222062, 疫苗免疫策略临床评价关键技术及应用, 2023-01-01至2025-12-31, 200万元, 资助期满, 主持;
3. 国家自然科学基金委员会, 面上项目, 82173584, 腺病毒载体新冠疫苗与灭活新冠疫苗诱导的免疫应答特征及序贯免疫策略研究, 2022-01-01至2025-12-31, 55万元, 资助期满, 主持。
代表性论文：(#Co-first author,*Co-corresponding author)
(1)Jin, Peng-Fei #; Quan #, Ya-Ru; Xiu #, Shi-Xin; Jiang, Xian-Min; Pan, Hong-Xing; Shen, Yuan;
Wang, Xu-Wen; Kong, Jian; Wang, Wen-Juan; Cao, Xiang; Xu, Kang-Wei; Yang, Min; Yang, Kun; Wan,Wen-Yan; Wang, Kai-Qin; Chen, Li; Yao, Ai-Hua; Xue, Yu-Peng; Wan, Na; Xu, Ming; Tao, Shi-Yao;Peng, Ling*; Yan, Fang-Rong*; Li, Chang-Gui*; Li, Jing-Xin*; Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial, Nature Communications, 2025, 16(1)
(2) Jia, Siyue#; Liu, Yuanbao#; He, Qian#; Pan, Hongxing; Liang, Zhenglun; Zhou, Juan; Pan,Yingzi; Liu, Sheng; Wu, Jingjing; Yang, Kun; Zhang, Xuanxuan; Zhao, Yang; Li, Simin; Zhang, Lei;Chen, Li; Yao, Aihua; Lu, Mengyi; Zhu, Fengcai*; Mao, Qunying*; Li, Jingxin*; Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China, Nature Communications,2025, 16(1)
(3) Siyue Jia#; Zundong Yin#; Hongxing Pan; Fuzhen Wang; Xiaoqiang Liu; Qing Wang; Li Zhang;Jihai Tang; Hao Yang; Jiangbo Du; Zhiguo Wang; Pengfei Jin; Zhihang Peng; Rong Tang; Guodong Kang; Xuewen Wang; Simin Li; Weixiao Wang; Jingxin Li*; Hongbing Shen*; Fengcai Zhu*; Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study, Emerging Microbes Infections, 2024, 13(1)
(4) Rong Tang#; Hui Zheng#; Bu-Sen Wang#; Jin-Bo Gou#; Xi-Ling Guo; Xiao-Qin Chen; Yin Chen; ShiPo Wu; Jin Zhong; Hong-Xing Pan; Jia-Hong Zhu; Xiao-Yu Xu; Feng-Juan Shi; Zhuo-Pei Li; Jing-Xian Liu; Xiao-Yin Zhang; Lun-Biao Cui; Zhi-Zhou Song; Li-Hua Hou*; Feng-Cai Zhu*; Jing-Xin Li*; Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial, The Lancet Respiratory Medicine, 2023, 11(7)
(5) Jing-Xin Li#; Li-Hua Hou#; Jin-Bo Gou; Zun-Dong Yin; Shi-Po Wu; Fu-Zhen Wang; Zhe Zhang; Zhi-Hang Peng; Tao Zhu; Hong-Bing Shen*; Wei Chen*; Feng-Cai Zhu*; Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multi-centre, open-label phase 3 trial, The Lancet Infectious Diseases, 2023, 23(10)